구조모아 (StructureMoa)항암 chemical structure spider web
방문UCB
분석
큐레이션 브리핑
경쟁 포지션: Efficacy leader in psoriasis clearance versus IL-17A-only and IL-23 agents.
기전. Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
IL-17A / IL-17F
Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa
US, EU, JP
Approved
bimzelx · bimekizumab · Bimzelx · UCB4940 · bimekizumab-bkzx
2026-09-10
Data Confidence · High
Development Signal · Established
Humanized IgG1 monoclonal antibody
Single antibody with cross-reactive binding to IL-17A, IL-17F, and the IL-17A/F heterodimer
IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance.
구조화 데이터
IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance.
Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes.
Humanized IgG1 monoclonal antibody
IL-17A / IL-17F · PASI/IGA response, hs-CRP in axial disease.
Oral candidiasis management; IBD and suicidal ideation monitoring per label
Efficacy leader in psoriasis clearance versus IL-17A-only and IL-23 agents.
Moderate-to-severe plaque psoriasis, active PsA, nr-axSpA and AS, moderate-to-severe HS
1L–2L biologic
Subcutaneous
320 mg q4w then q8w (indication-dependent)
Oral candidiasis management; IBD and suicidal ideation monitoring per label
Efficacy leader in psoriasis clearance versus IL-17A-only and IL-23 agents.
Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone.
N/A — the mechanism is cytokine suppression.
PASI/IGA response, hs-CRP in axial disease.
Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes.
구조화 데이터
Human, cynomolgus
~23 days
PASI 90/100, HiSCR in HS, ASAS40 in axSpA
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (plaque psoriasis)
APPROVAL · 2023년 10월
PsA, nr-axSpA, and AS indications
APPROVAL · 2024년 9월
Hidradenitis suppurativa indication
APPROVAL · 2024년 10월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
UCB
분석
큐레이션 브리핑
경쟁 포지션: Efficacy leader in psoriasis clearance versus IL-17A-only and IL-23 agents.
기전. Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
IL-17A / IL-17F
Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa
US, EU, JP
Approved
bimzelx · bimekizumab · Bimzelx · UCB4940 · bimekizumab-bkzx
2026-09-10
Data Confidence · High
Development Signal · Established
Humanized IgG1 monoclonal antibody
Single antibody with cross-reactive binding to IL-17A, IL-17F, and the IL-17A/F heterodimer
IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance.
구조화 데이터
IL-17F contributes independently to tissue inflammation, so blocking it as well raises the ceiling on complete skin clearance.
Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes.
Humanized IgG1 monoclonal antibody
IL-17A / IL-17F · PASI/IGA response, hs-CRP in axial disease.
Oral candidiasis management; IBD and suicidal ideation monitoring per label
Efficacy leader in psoriasis clearance versus IL-17A-only and IL-23 agents.
Moderate-to-severe plaque psoriasis, active PsA, nr-axSpA and AS, moderate-to-severe HS
1L–2L biologic
Subcutaneous
320 mg q4w then q8w (indication-dependent)
Oral candidiasis management; IBD and suicidal ideation monitoring per label
Efficacy leader in psoriasis clearance versus IL-17A-only and IL-23 agents.
Binds IL-17A and IL-17F, preventing engagement of the IL-17RA/RC complex and shutting down downstream keratinocyte and synovial inflammatory signaling more completely than IL-17A blockade alone.
N/A — the mechanism is cytokine suppression.
PASI/IGA response, hs-CRP in axial disease.
Anti-drug antibodies and non-IL-17-driven inflammatory phenotypes.
구조화 데이터
Human, cynomolgus
~23 days
PASI 90/100, HiSCR in HS, ASAS40 in axSpA
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (plaque psoriasis)
APPROVAL · 2023년 10월
PsA, nr-axSpA, and AS indications
APPROVAL · 2024년 9월
Hidradenitis suppurativa indication
APPROVAL · 2024년 10월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.